METHODS OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST
AssigneeFerring B.V.
InventorsTine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A. van der Meulen, Jens-Kristian Slott Jensen
Life of this patent
Estimating the term…
Abstract
The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
Claims19
1-89. (canceled)
A method of treating advanced stage prostate cancer in a subject, comprising:
- administering an initial dose of 160-320 mg of degarelix to the subject and a maintenance dose of 60-160 mg of degarelix to the subject, wherein the maintenance dose is administered once every 20-36 days thereafter,
- wherein the treated subject has a decreased likelihood of developing arthralgia or musculoskeletal stiffness during treatment compared to a treatment with a gonadotrophin releasing hormone (GnRH) agonist.
A method of treating advanced stage prostate cancer in a subject, comprising:
- administering an initial dose of 160-320 mg of degarelix to the subject and a maintenance dose of 60-160 mg of degarelix to the subject, wherein the maintenance dose is administered once every 20-36 days thereafter,
- wherein the treated subject has a decreased likelihood of developing noninfective cystitis during treatment compared to a treatment with a gonadotrophin releasing hormone (GnRH) agonist.
A method of treating advanced stage prostate cancer in a subject, comprising:
- administering an initial dose of 160-320 mg of degarelix to the subject and a maintenance dose of 60-160 mg of degarelix to the subject, wherein the maintenance dose is administered once every 20-36 days thereafter,
- wherein the treated subject has a decreased likelihood of developing a urinary or renal system disorder during treatment compared to a treatment with a gonadotrophin releasing hormone (GnRH) agonist.
A method of treating advanced stage prostate cancer in a subject, comprising:
- administering an initial dose of 160-320 mg of degarelix to the subject and a maintenance dose of 60-160 mg of degarelix to the subject, wherein the maintenance dose is administered once every 20-36 days thereafter,
- wherein the treated subject has a decreased likelihood of developing erectile dysfunction during treatment compared to a treatment with a gonadotrophin releasing hormone (GnRH) agonist.
A method of treating advanced stage prostate cancer in a subject, comprising:
- administering an initial dose of 160-320 mg of degarelix to the subject and a maintenance dose of 60-160 mg of degarelix to the subject, wherein the maintenance dose is administered once every 20-36 days thereafter,
- wherein the treated subject has at least about a 50% decrease in prostate specific antigen (PSA) by day 14 of treatment.
Dependencies are inferred from the claim text.